drugset / Trial / NCT01485146

A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects

NCT01485146

Phase 1 Completed 24 enrolled Esperion Therapeutics, Inc.
RandomizedSingle-groupDouble-blindTreatment

Summary

This Phase 1, double-blind (sponsor open), placebo controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 in healthy subjects.

Timeline

Start
2011-10-25
Primary completion
2012-01-25
Completion
2012-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Bempedoic acid Small molecule

Indications

No indication recorded.